Abstract
Erectile dysfunction occurs extensively among patients with arterial hypertension. We investigated the safety of sildenafil for patients with and without antihypertensive medication. Our study included data from 35 double-blind, placebo- controlled, and randomized investigations, with a total of 8115 patients. The term of therapy was between 6 weeks and 6 months, for both the sildenafil group (5-200 mg, n = 4819) as well as the placebo group (n = 3296). We studied the adverse events in the men who received 1 or more hypertensives (n = 2388), and in those who took no antihypertensive medication (n = 5727). Our findings disclosed equal frequency of adverse events in both groups, without influence by the number of different antihypertensives administered. The occurrence of AEs associated with blood pressure was slight, and was comparable between the individual groups. These results support the conclusion that sildenafil is also well tolerated by patients taking one or more antihypertensives. Patients being treated with alpha blockers should be stable on this therapy in order to minimize the possibility of orthostatic hypotension. An initial dose of 25 mg should furthermore be considered for these patients.
Keywords: endothelium, antihypertensives, nitric oxide, c-GMP, hypotonsion
Current Drug Safety
Title: Sildenafil is Well Tolerated by Erectile Dysfunction Patients Taking Antihypertensive Medications, Including Those on Multidrug Regimens
Volume: 2 Issue: 1
Author(s): Marko Bohm, Martin Burkart and Gert Baumann
Affiliation:
Keywords: endothelium, antihypertensives, nitric oxide, c-GMP, hypotonsion
Abstract: Erectile dysfunction occurs extensively among patients with arterial hypertension. We investigated the safety of sildenafil for patients with and without antihypertensive medication. Our study included data from 35 double-blind, placebo- controlled, and randomized investigations, with a total of 8115 patients. The term of therapy was between 6 weeks and 6 months, for both the sildenafil group (5-200 mg, n = 4819) as well as the placebo group (n = 3296). We studied the adverse events in the men who received 1 or more hypertensives (n = 2388), and in those who took no antihypertensive medication (n = 5727). Our findings disclosed equal frequency of adverse events in both groups, without influence by the number of different antihypertensives administered. The occurrence of AEs associated with blood pressure was slight, and was comparable between the individual groups. These results support the conclusion that sildenafil is also well tolerated by patients taking one or more antihypertensives. Patients being treated with alpha blockers should be stable on this therapy in order to minimize the possibility of orthostatic hypotension. An initial dose of 25 mg should furthermore be considered for these patients.
Export Options
About this article
Cite this article as:
Bohm Marko, Burkart Martin and Baumann Gert, Sildenafil is Well Tolerated by Erectile Dysfunction Patients Taking Antihypertensive Medications, Including Those on Multidrug Regimens, Current Drug Safety 2007; 2 (1) . https://dx.doi.org/10.2174/157488607779315462
DOI https://dx.doi.org/10.2174/157488607779315462 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Entry of Oximes into the Brain: A Review
Current Medicinal Chemistry Targeting Trail Towards the Clinic
Current Drug Targets Iron Chelating Strategies in Systemic Metal Overload, Neurodegeneration and Cancer
Current Medicinal Chemistry Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds
Current Medicinal Chemistry Drugs for AIDS
Mini-Reviews in Medicinal Chemistry Molecular Basis of Mineralocorticoid Receptor Action in the Nervous System
CNS & Neurological Disorders - Drug Targets Isometric Handgrip Effects on Hypertension
Current Hypertension Reviews Molecular Basis of Adrenomedullin 1 Receptor Function and Its Roles in the Cardiovascular System
Current Hypertension Reviews Perinatal Brain Injury
Current Pediatric Reviews The Chromogranin A-Derived Vasostatins: New Players in the Endocrine Heart
Current Medicinal Chemistry Mitochondrial Dysfunction and Antioxidant Therapy in Sepsis
Infectious Disorders - Drug Targets New Mucoadhesive Polymeric Film for Ophthalmic Administration of Acetazolamide
Recent Patents on Drug Delivery & Formulation High-output Cardiac Failure: A Forgotten Phenotype in Clinical Practice
Current Cardiology Reviews Role of Renin-Angiotensin-Aldosterone System in Metabolic Syndrome and Obesity-related Hypertension
Current Hypertension Reviews Phytochemical and Pharmacological Activity Profile of Crataegus oxyacantha L. (Hawthorn) - A Cardiotonic Herb
Current Medicinal Chemistry Inflammatory Caspases: Targets for Novel Therapies
Current Pharmaceutical Design Therapeutic Strategies for Alzheimer's and Parkinson's Diseases by Means of Drug Delivery Systems
Current Medicinal Chemistry Simultaneous Determination of Cytochrome P450 Oxidation Capacity in Humans: A Review on the Phenotyping Cocktail Approach
Current Pharmaceutical Biotechnology The Burden of Metabolic Diseases Amongst HIV Positive Patients on HAART Attending the Johannesburg Hospital
Current HIV Research Basic and Clinical Aspects of Gene Therapy for Retinopathy Induced by Diabetes
Current Gene Therapy